To prepare PEGylated recombinant human granulocyte colony-stimulating factor (rHuG-CSF) with enhanced pharmacokinetic properties, we prepared a cysteine-substituted mutant of rHuG-CSF (mrHuG-CSF). For site-specific PEGylation of mrHuG-CSF, Threonine 134 residue that is one of the glycosylation sites and thought not to be critical in structure and function of rHuG-CSF was substituted by Cysteine...

PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected. The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as im...

FABMS analysis of T-lb peptide before and after one cycle of Edman degradation indicated an unblocked N-terminal Thr residue for this tryptic peptide. In contrast , our data showed a molecular protonated ion, MH + for T- la peptide at 655 mass units (mu) which is 42 mu higher than the MH ion of T- 1b peptide. In addition, T- la peptide was not amenable to one cycle of manual Edman degrada...

Antimicrobial peptides (AMPs) have therapeutic potential, particularly for localized infections such as those of the lung. Here we show that airway administration of a pegylated AMP minimizes lung tissue toxicity while nevertheless maintaining antimicrobial activity. CaLL, a potent synthetic AMP (KWKLFKKIFKRIVQRIKDFLR) comprising fragments of LL-37 and cecropin A peptides, was N-terminally pegy...

Covalent grafting of poly(ethylene glycol) (PEG) to pharmaceutical proteins, "PEGylation", is becoming more commonplace due to improved therapeutic efficacy. As these conjugates encounter interfaces in manufacture, purification, and end use and adsorption to these interfaces may alter achievable production yields and in vivo efficacies, it is important to understand how PEGylation affects prote...

Alginate lyase enzymes represent prospective biotherapeutic agents for treating bacterial infections, particularly in the cystic fibrosis airway. To effectively deimmunize one therapeutic candidate while maintaining high level catalytic proficiency, a combined genetic engineering-PEGylation strategy was implemented. Rationally designed, site-specific PEGylation variants were constructed by orth...

fabms analysis of t-lb peptide before and after one cycle of edman degradation indicated an unblocked n-terminal thr residue for this tryptic peptide. in contrast , our data showed a molecular protonated ion, mh + for t- la peptide at 655 mass units (mu) which is 42 mu higher than the mh ion of t- 1b peptide. in addition, t- la peptide was not amenable to one cycle of manual edman degradation. ...